Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel T… – Press Release - CayPress

Sunday, July 30, 2023

Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel T… – Press Release


RADNOR, Pa., July 30, 2023 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc. (“BioXcel”) ((BTAI). The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of BioXcel’s materially misleading statements and omissions to the public, BioXcel’s investors have suffered significant losses.

CLICK HERE TO SUBMIT YOUR BIOXCEL LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://ift.tt/3WstoXa

TO VIEW OUR VIDEO, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: SEPTEMBER 5, 2023

CLASS PERIOD: DECEMBER 15, 2021 THROUGH JUNE 28, 2023

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or via email at info@ktmc.com  

Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

BIOXCEL’S ALLEGED MISCONDUCT
On December 15, 2021, BioXcel announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease. BioXcel stated that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III. The studies were purportedly designed to evaluate the safety and efficacy of BXCL501 in adults 65 years and older across the range…



The post Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel T… – Press Release appeared first on CaymanMama.com.



from CaymanMama.com https://ift.tt/RSJgdUA

No comments:

Post a Comment